AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26122756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active go/no-go training with high-energy density snack foods
Number of subjects: 83
Study 26122756 — intervention group
Group type: COMPARATOR
Intervention: Control go/no-go training with non-food stimuli
Number of subjects: 83
Study 26122756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 83
Study 26122756 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 83
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 155
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlor‐XTRA Vista
Number of subjects: 155
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoclean
Number of subjects: 155
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 155
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sodium hypochlorite/17% EDTA
Number of subjects: 155
Study 24933773 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA (used at the end of root canal preparation)
Number of subjects: 155
Study 24933773 — intervention group
Group type: COMPARATOR
Intervention: Positive control (single gutta‐percha cone without sealer)
Number of subjects: 155
Study 24933773 — intervention group
Group type: COMPARATOR
Intervention: Negative control (obturated in the same way as experimental groups)
Number of subjects: 155
Study 23046330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted CAS
Number of subjects: 22
Study 23046330 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone CAS
Number of subjects: 22
Study 19281966 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 202
Study 19281966 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 202
Study 19281966 — intervention group
Group type: COMPARATOR
Intervention: Suppression
Number of subjects: 202
Study 17488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily for 6 weeks
Number of subjects: 16
Study 17488800 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg daily for 6 weeks
Number of subjects: 16
Study 16054412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low normal protein content (LNP) diet (10 E%; 0.9 g protein/kg body weight)
Number of subjects: 12
Study 16054412 — intervention group
Group type: COMPARATOR
Intervention: High normal protein content (HNP) diet (20 E%; 1.8 g protein/kg body weight)
Number of subjects: 12
Study 16054412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low normal protein content (LNP) diet
Number of subjects: 12
Study 16054412 — intervention group
Group type: COMPARATOR
Intervention: High normal protein content (HNP) diet
Number of subjects: 12
Study 12398257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg during week 1, 100 mg during week 2, 150 mg during weeks 3, 4, and 5)
Number of subjects: 19
Study 12398257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19
Study 12398257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10390029 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphoria (positive condition of the Velten Mood Induction Procedure)
Number of subjects: 60
Study 10390029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoria (negative condition of the Velten Mood Induction Procedure)
Number of subjects: 60
Study 7880710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy control of isoflurane concentration
Number of subjects: 10
Study 7880710 — intervention group
Group type: COMPARATOR
Intervention: Human control of isoflurane concentration
Number of subjects: 10
Study 2223676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for bed rest
Number of subjects: 118
Study 2223676 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 118
Study 261957 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/die)
Number of subjects: 30
Study 261957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31424568 — intervention group
Group type: COMPARATOR
Intervention: 5FU/LV
Number of subjects: 4949
Study 31424568 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 4949
Study 31424568 — intervention group
Group type: COMPARATOR
Intervention: Any adjuvant treatment
Number of subjects: 4949
Study 30502501 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-CBT
Number of subjects: 90
Study 28341243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-preserved gel solution of carboxymethylcellulose
Number of subjects: 2
Study 28341243 — intervention group
Group type: COMPARATOR
Intervention: Non-preserved saline
Number of subjects: 2
Study 28341243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2
Study 25813300 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 stimulation
Number of subjects: 56
Study 25813300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no P6 stimulation)
Number of subjects: 56
Study 23691829 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning in a simulated environment
Number of subjects: 0
Study 23691829 — intervention group
Group type: COMPARATOR
Intervention: Articulatory suppression (affecting working memory)
Number of subjects: 0
Study 23691829 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the simulated environment
Number of subjects: 0
Study 21642529 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive dental video game teaching the three‐step etch‐and‐rinse resin bonding system
Number of subjects: 80
Study 21642529 — intervention group
Group type: COMPARATOR
Intervention: Clinical video recording of the three‐step etch‐and‐rinse resin bonding system
Number of subjects: 80
Study 19500003 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered Nigella sativa (Kalonji) seed in capsules
Number of subjects: 123
Study 19500003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 16458688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovereign with WhiteStar (SWS) system
Number of subjects: 26
Study 16458688 — intervention group
Group type: COMPARATOR
Intervention: Legacy with AdvanTec and NeoSoniX (LAD) system
Number of subjects: 26
Study 16458688 — intervention group
Group type: COMPARATOR
Intervention: Legacy with AdvanTec and NeoSoniX (LAD) system (cataract density of 4)
Number of subjects: 26
Study 14984521 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP group (n = 20) - pre-oxygenated using 100% O2 with CPAP (6 cmH2O) for 5 min, followed by mechanical ventilation with PEEP 6 cm H2O for 5 min
Number of subjects: 40
Study 14984521 — intervention group
Group type: COMPARATOR
Intervention: ZEEP group (n = 20) - no CPAP or PEEP used
Number of subjects: 40
Study 10051763 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (partial opioid agonist)
Number of subjects: 0
Study 10051763 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (10 mg)
Number of subjects: 0
Study 7747291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg every 12 h for 3 days
Number of subjects: 75
Study 7747291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg every 6 h for 3 days
Number of subjects: 75
Study 7747291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid 500 mg every 6 h for 3 days
Number of subjects: 75
Study 7747291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 500 mg every 6 h for 3 days
Number of subjects: 75
Study 7747291 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (control group)
Number of subjects: 75
Study 2106804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine boluses
Number of subjects: 22
Study 2106804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ranitidine infusions
Number of subjects: 22
Study 2106804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ranitidine infusions with enteral nutrition via nasogastric tube
Number of subjects: 22
Study 2106804 — intervention group
Group type: COMPARATOR
Intervention: Other therapeutic regimens (pirenzepine and sucralfate)
Number of subjects: 22
Study 6991105 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 101
Study 6991105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31744401 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% rapid weight loss (RWL)
Number of subjects: 9
Study 31744401 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 31888511 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope-guided technique
Number of subjects: 119
Study 31888511 — intervention group
Group type: COMPARATOR
Intervention: Standard digital technique
Number of subjects: 119
Study 27469537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hand therapy visit at 10-14 days postoperatively
Number of subjects: 134
Study 24614837 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 100 mg/kg/day
Number of subjects: 80
Study 22293678 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 6
Study 22293678 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warm-up (PW)
Number of subjects: 6
Study 22293678 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 6
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline solution at 100% maintenance rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline solution at 50% maintenance rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution at 100% maintenance rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution at 50% maintenance rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid type (0.45% vs 0.9% saline)
Number of subjects: 124
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% maintenance rate
Number of subjects: 124
Study 19818450 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% maintenance rate
Number of subjects: 124
Study 16954337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme substitution (PES)
Number of subjects: 8
Study 15694213 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (multidisciplinary depression treatment program with care manager support)
Number of subjects: 1801
Study 15694213 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 1801
Study 15694213 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 12001042 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen of abacavir-lamivudine-zidovudine (n=84)
Number of subjects: 163
Study 12001042 — intervention group
Group type: COMPARATOR
Intervention: Continuation with protease inhibitor plus nucleoside-analogue combination regimens (n=79)
Number of subjects: 163
Study 12001042 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen of abacavir-lamivudine-zidovudine
Number of subjects: 163
Study 10190835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad lib feeding regimen
Number of subjects: 78
Study 10190835 — intervention group
Group type: COMPARATOR
Intervention: Prescribed feeding regimen
Number of subjects: 78
Study 10190835 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-calorie formula
Number of subjects: 78
Study 10190835 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-calorie formula
Number of subjects: 78
Study 7768298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 micrograms) administered twice daily for 2 weeks
Number of subjects: 24
Study 7768298 — intervention group
Group type: COMPARATOR
Intervention: House dust mite extract nasal challenge
Number of subjects: 24
Study 2180106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 40 mg per day for 14 days
Number of subjects: 121
Study 2180106 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 500 micrograms thrice daily for 14 days
Number of subjects: 121
Study 2180106 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 121
Study 7256808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy schemes (external and intracavitary radiations given alternately with unequal doses)
Number of subjects: 0
Study 7256808 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified approximate CRE and nominal dose methods
Number of subjects: 0
Study 31506096 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneously increase exercise and fruit/vegetable intake, while decreasing sedentary leisure screen time
Number of subjects: 340
Study 31506096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially increase fruit/vegetable intake and decrease leisure screen time first, then increase exercise
Number of subjects: 340
Study 31506096 — intervention group
Group type: COMPARATOR
Intervention: Increase sleep and decrease stress (control)
Number of subjects: 340
Study 28526493 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREFuL (Care Programme for the Last Days of Life)
Number of subjects: 451
Study 28526493 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 451
Study 26068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (telephone follow-up with serum β‐hCG and symptom checklist)
Number of subjects: 129
Study 26068140 — intervention group
Group type: COMPARATOR
Intervention: Standard in-clinic follow-up (ultrasound and assessment)
Number of subjects: 129
Study 24526708 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroneal nerve functional electrical stimulation (FES)
Number of subjects: 495
Study 24526708 — intervention group
Group type: COMPARATOR
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 495
Study 22211512 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, progressive resistance and functional group training for 3 months (intervention group, n=62)
Number of subjects: 122
Study 22211512 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity motor placebo activity (control group, n=60)
Number of subjects: 122
Study 18036144 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline (normal saline)
Number of subjects: 50
Study 18036144 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% dextrose and 0.18% saline (dextrose saline)
Number of subjects: 50
Study 18036144 — intervention group
Group type: EXPERIMENTAL
Intervention: Full maintenance rate
Number of subjects: 50
Study 18036144 — intervention group
Group type: COMPARATOR
Intervention: Restricted rate
Number of subjects: 50
Study 17531931 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ perindopril
Number of subjects: 159
Study 17531931 — intervention group
Group type: COMPARATOR
Intervention: Atenolol +/‐ bendroflumethiazide
Number of subjects: 159
Study 16945514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg of pentastarch (group A)
Number of subjects: 70
Study 16945514 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg of pentastarch (group B)
Number of subjects: 70
Study 15156783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral hemispheric infarcts (with or without neglect)
Number of subjects: 0
Study 15156783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hemispatial neglect
Number of subjects: 0
Study 15156783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hemianopia
Number of subjects: 0
Study 15156783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right-hemisphere lesions
Number of subjects: 0
Study 15156783 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 10987233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy and systemic treatment
Number of subjects: 84
Study 10987233 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment alone
Number of subjects: 84
Study 8800358 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CO2 inhalation during exhaustive maximal two‐legged cycling
Number of subjects: 5
Study 8800358 — intervention group
Group type: COMPARATOR
Intervention: No CO2 inhalation during exhaustive maximal two‐legged cycling
Number of subjects: 5
Study 1815226 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-vasopressin (AVP)
Number of subjects: 40
Study 1815226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6336641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicozamycin (500 mg orally four times daily for 3 days)
Number of subjects: 140
Study 6336641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicozamycin
Number of subjects: 140
Study 6336641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31136456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric resuscitation
Number of subjects: 37
Study 31136456 — intervention group
Group type: COMPARATOR
Intervention: Adult resuscitation
Number of subjects: 37
Study 31689072 — intervention group
Group type: EXPERIMENTAL
Intervention: XylS mutants recognizing p-toluic acid; specific mutations include T74P and N7R.
Number of subjects: 0
Study 31689072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual selection system for directed evolution of XylS.
Number of subjects: 0
Study 29265040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care Group (PC)
Number of subjects: 200
Study 29265040 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UC)
Number of subjects: 200
Study 27124825 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 2‐screw cephalomedullary nail (InterTan)
Number of subjects: 104
Study 27124825 — intervention group
Group type: COMPARATOR
Intervention: Single-screw device (Gamma3)
Number of subjects: 104
Study 24400655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M) 12.5/500 mg BID
Number of subjects: 784
Study 24400655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M) 12.5/1000 mg BID
Number of subjects: 784
Study 24400655 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin (A) 12.5 mg BID
Number of subjects: 784
Study 24400655 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M) 500 mg BID
Number of subjects: 784
Study 24400655 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M) 1000 mg BID
Number of subjects: 784
Study 24400655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M)
Number of subjects: 784
Study 24400655 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin (A) and Metformin (M) monotherapies
Number of subjects: 784
Study 22932329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation therapy
Number of subjects: 60
Study 22932329 — intervention group
Group type: COMPARATOR
Intervention: Crescent conjunctival resection
Number of subjects: 60
Study 19772761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei strain KW3110
Number of subjects: 126
Study 19772761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 17273815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic repair (onlay polypropylene mesh)
Number of subjects: 42
Study 17273815 — intervention group
Group type: COMPARATOR
Intervention: Tissue repair
Number of subjects: 42
Study 15149251 — intervention group
Group type: EXPERIMENTAL
Intervention: Task span procedure with lists of 1-10 task names and stimuli to perform tasks.
Number of subjects: 70
Study 15149251 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice with consistent and varied lists.
Number of subjects: 70
Study 15149251 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the number of task switches.
Number of subjects: 70
Study 11403192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cidofovir cream
Number of subjects: 12
Study 11403192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9557925 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 12
Study 9557925 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 7999500 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 2
Study 7999500 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 2
Study 3386087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 15 mg/day
Number of subjects: 6
Study 3386087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 7.5 mg/day
Number of subjects: 6
Study 3386087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31502420 — intervention group
Group type: EXPERIMENTAL
Intervention: Muse
Number of subjects: 15
Study 31502420 — intervention group
Group type: EXPERIMENTAL
Intervention: DayDream
Number of subjects: 15
Study 31502420 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild Divine
Number of subjects: 15
Study 31048758 — intervention group
Group type: COMPARATOR
Intervention: ADM AG genotype (vs. ADM GG genotype) in boys
Number of subjects: 675
Study 31048758 — intervention group
Group type: COMPARATOR
Intervention: ADM AG+AA genotype (vs. ADM GG genotype) in boys
Number of subjects: 675
Study 31048758 — intervention group
Group type: COMPARATOR
Intervention: ADM AG genotype (vs. ADM GG+AA genotype) in boys
Number of subjects: 675
Study 31048758 — intervention group
Group type: COMPARATOR
Intervention: ADM AG+AA genotype (vs. ADM GG genotype) in girls
Number of subjects: 675
Study 31048758 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM gene polymorphism
Number of subjects: 675
Study 28604375 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy leaving in situ the wisdom upper third molars (Group A)
Number of subjects: 20
Study 28604375 — intervention group
Group type: COMPARATOR
Intervention: Le Fort I osteotomy after extraction of the wisdom upper third molars (Group B)
Number of subjects: 20